ORIGINAL ARTICLE

Prognostic value of 18F-FDG PET/CT parameters and histopathologic variables in head and neck cancer

Hale Aslan a,*, Gul Cekin b, Ercan Pinar a, Mustafa Yazir a, Abdulkadir Imre a, Murat Songu a, Akif Islek c, Ibrahim Aladag a, Ismail Semih Oncel a

a Katip Celebi University School of Medicine, Department of Otolaryngology Head and Neck Surgery, Izmir, Turkey
b Katip Celebi University School of Medicine, Department of Nuclear Medicine, Izmir, Turkey
c Mardin Nusaybin State Hospital, Mardin, Turkey

Received 20 September 2019; accepted 28 October 2019
Available online 10 December 2019

KEYWORDS
Head and neck cancer
18F-FDG PET/CT;
Prognosis;
Metabolic parameters

Abstract
Introduction: 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters such as; maximum standardized uptake values, standard metabolic tumor volume and total lesion glycosis are important prognostic biomarkers in cancers. Objective: To investigate the prognostic value of these parameters in patients with head and neck cancers.
Methods: We performed a retrospective study including 47 patients with head and neck cancer who underwent 18F-fluorodeoxyglucose positron emission tomography/computed tomography prior to treatment. Standard metabolic tumor volume, total lesion glycosis and standardized uptake were measured for each patient. The prognostic value of quantitative 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters and clinicopathologic variables on disease free survival and overall survival were analyzed.
Results: The median (range) standard metabolic tumor volume and total lesion glycosis and standardized uptake were 7.63 cm³ (0.6–34.3), 68.9 g (2.58–524.5 g), 13.89 (4.89–33.03 g/mL), respectively. Lymph node metastases and tumour differentiation were significant variables for disease free survival and overall survival, however, all 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters were not associated with disease- free survival and overall survival.
Conclusion: Pretreatment quantities positron emission tomography parameters did not predict survival in head and neck cancer.
© 2019 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

* Corresponding author.
E-mail: drhaleaslan@gmail.com (H. Aslan).
Peer Review under the responsibility of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.

https://doi.org/10.1016/j.bjorl.2019.10.014
1808-8694/© 2019 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction

Head and neck carcinomas are an important cause of mortality in humans. Head and neck carcinomas are clinically heterogeneous entities that show disparities in natural course or clinical behaviour depends on the tumor location and histopathologic variables such as, tumor size, stage, lymph node metastases, surgical margin and lymphovascular invasion. However, despite careful evaluation of these factors, it is not possible to reliably predict the outcome of treatment inpatients. 

18F-FDG PET/CT is based on tumour glucose metabolism and serves as a marker of tumour metabolic activity in terms of cell viability and proliferation. It has been successfully applied in pre-treatment staging, treatment response assessment and post treatment follow-up. It is superior to computed tomography and magnetic resonance imaging in the detection of carcinomas of unknown primary, cervical lymph node or distant metastasis.

Recently, 18F-FDG Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG), combining the tumour volume and metabolic activity of the entire tumor have been introduced as prognostic biomarkers in various solid malignancies, however their prognostic values are not well established. The value of MTV was already identified in patients with HNSCC who received radiotherapy. In particular, the question of which is the better parameter to predict outcome remains unresolved.

We performed this retrospective study to determine the yield of pretreatment quantitative 18F-FDG PET/CT parameters and histopathologic variables for the prediction of OS, DFS and lymph node metastasis.

Methods

This retrospective study was approved by the institutional review board (19-12-2018/423).

Patients

The population of this retrospective study consisted of patients with locally advanced head and neck squamous cell carcinoma involving oropharynx, hypopharynx, oral cavity and larynx who had FDG PET/CT for initial staging between January 2015 and June 2016. Exclusion criteria were non-squamous cell carcinoma histology, previous treatment, and evidence of distant metastasis. Cancers originating in the salivary gland, thyroid and paranasal sinuses were also excluded. 47 patients were included in this study. All patients underwent surgical resection of primary tumour with cervical neck dissection, followed by radiotherapy with or without concurrent chemotherapy. Indications for postoperative adjuvant therapy relied on postoperative pathologic features. All patients were followed at least two years.

F-FDG PET/CT

Patients with glucose level lower than 200 mg/dL fasted for 6 h prior to intravenous infusion of 0.1 mCi/kg 18F-FDG. PET/CT was performed on GE Discovery 710. CT (50 mAs, 120 kV, 3.75 mm section thickness) was performed without intravenous contrast administration. PET scan was performed immediately after CT and whole body images from skull base to upper thigh were scanned on average 7–8 bed positions (2 min per bed position).

Image analysis

Volumetric region of interest were placed over areas of abnormal 18F-FDG uptake. Standardized uptake values (SUVmax and SUVmean), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) of primary tumor and neck lymph nodes were evaluated for each patient. A threshold of 42 % of maximum signal intensity was used to delineate the MTV. TLG was calculated as the product of lesion means standardized uptake value and MTV. FDG uptake was defined to be positive qualitatively when a focal FDG uptake was higher than the normal biodistribution of background FDG activity. After correlating abnormal CT findings, increased focal FDG uptake was accepted pathological diseases. When the positive lymph nodes were evaluated, its size and metabolic activity were described. In the presence of more than one lymph node, anatomically the largest one and the most active lymph nodes were described.

Statistical analysis

All statistical analysis was performed using the SPSS windows 15.0 software (SPSS, Chicago, Illionis). Univariate analysis was used to identify clinical factors and imaging parameters predictive of Disease-Free Survival (DFS) and Overall Survival (OS) by using the X2 or Fisher’s exact test. We determined the cut-off values for various FDG-uptake parameters (SUVmax, MTV, TLG). Disease free survival and overall survival curves were calculated using the Kaplan-Meier method. The log-rank test was used to compare survival rates according to imaging parameters. In the univariate analysis, all patients were separated into 2 groups based on the SUVmax, MTV and TLG. The relationships between the two groups of each FDG-uptake parameters with survival and lymph node metastases were compared using χ2 test. A value of p less than 0.05 was considered significant.

Results

Patient characteristics

47 patients were included in this study. The study group was composed of 40 male and 7 female patients with the mean age of 63 years (range 43–89 years). All patients included in this study were diagnosed with locally HNSCC, including 16 TNM stage IV, 15 Stage III and 16 Stage II. The larynx was the most common site of primary tumour, observed in 31 patients (65.9 %). Poor differentiation were observed in 20 patients (42.5 %). The tumour progression was identified in 8 patients (17 %); in a local site in 2 (4 %) patients, in a regional site in 3 patients and distant sites in 3 patients in the follow-up. 39 patients were alive without disease for 3 years.
| Variables          | 3 year DFS (%) | p-value | 3 year OS (%) | p-value |
|--------------------|----------------|---------|---------------|---------|
| Lateral LN         |                | 0.051   |               | 0.044   |
| Metastatic         | 68             |         | 56            |         |
| Reactive           | 82             |         | 78            |         |
| TNM                |                | 0.0473  |               | 0.291   |
| Stage 1-2          | 92             |         | 92            |         |
| Stage 3-4          | 79             |         | 71            |         |
| Differentiation    |                | 0.012   |               |         |
| Poor dif           | 95             |         | 88            |         |
| Mild dif           | 83             |         | 82            |         |
| Well dif           | 67             |         | 47            |         |
| Tm size            |                | 0.769   |               | 0.477   |
| 0-2 cm             | 80             |         | 100           |         |
| 2-4 cm             | 82             |         | 73            |         |
| Up to 4 cm         | 90             |         | 80            |         |
| PN-PV inv          |                | 0.187   |               | 0.480   |
| PNor PV (+)        | 44             |         | 86            |         |
| PN or PV (-)       | 91             |         | 73            |         |
| Suv max            |                | 0.507   |               | 0.222   |
| ≥ Median level     | 84             |         | 80            |         |
| ≤ Median level     | 84             |         | 71            |         |
| TLG                |                | 0.560   |               | 0.168   |
| ≥ Median level     | 81             |         | 61            |         |
| ≤ Median level     | 86             |         | 94            |         |
| MTV                |                | 0.380   |               | 0.264   |
| ≥ Median level     | 75             |         | 51            |         |
| ≤ Median level     | 78             |         | 84            |         |

Assessed using the two-sided Fisher’s exact test or the \( \chi^2 \) test.

PN, Perineural Invasion; PV, Perivascular Invasion.

Figure 1  Survey analysis of \(^{18}\text{F-FDG PET/CT metabolic parameters.}\)
The median MTV, TLG and SUV$_{\text{max}}$ were 7.63 cm$^3$ (0.6–34.3), 68.9 g (2.58–524.5 g), 13.89 (4.89–33.03 g/mL), respectively. There was no significant relationship between PET parameters and survival. Only lateral lymph node metastases and tumor differentiation reached significance (Table 1). SUV$_{\text{max}}$, MTV and TLG values did not reach significance for patients with lymph node metastasis. TNM stage and perineural or perivascular invasion were significantly associated with lymph node metastases (Table 2). From the ROC curve analysis, the SUV$_{\text{max}}$, MTV and TLG cut-off values for patients with survival relationship were shown in Fig. 1.

### Discussion

FDG PET/CT simultaneously providing anatomical and functional information is useful for the detection of primary tumor metastases, synchronous primary tumor, RT planning, assessment of treatment response and surveillance for tumor recurrence and metastases after treatment. Functional imaging of FDG PET/CT can provide metabolic information on malignant tissues and make it possible to reflect the tumor burden more accurately. Various F-FDG PET parameters have been investigated in solid tumors, MTV, which is a measure of the volume of the tumor displaying F-FDG uptake and quantifies the overall tumor burden, is a better predictor of outcome than SUV$_{\text{max}}$. TLG have been developed to measure metabolic activity in an entire tumor mass. Therefore, volume-based parameters such as MTV and TLG may reflect the metabolic burden of the active tumor more accurately than SUV$_{\text{max}}$.

Many studies have shown that elevated MTV, TLG and SUV$_{\text{max}}$ values is associated with worse prognosis. Pretreatment SUV$_{\text{max}}$ has been used to evaluate the aggressiveness of disease, response to therapy, early detection of recurrence and outcome, however, previous studies and the present study showed that elevated MTV, TLG and SUV$_{\text{max}}$ values were not significantly associated with lymph node metastasis and survival. The risk of lymph node metastasis and decreased OS and DFS was not higher in patients with high MTV, TLG and SUV$_{\text{max}}$ values. High FDG uptake correlated with advanced pT and pN stages. However, the SUV$_{\text{max}}$ of primary tumor, including metastatic lymph nodes was not confirmed as a significant factor predicting clinical outcome in HNSCC patients. In our study, lower SUV$_{\text{max}}$ values did not demonstrate higher rates of OS and DFS with a statistical significance.

TNM stage, histopathologic parameters are important prognostic factors in HNSCC. Pathologic T and N stages were significant predictive factors of clinical outcome in the study by Le Tourneau et al. On the contrary, other studies showed different results and pT and pN stages did not predict treatment outcome and survival. In this study, stage and perineural or perivascular invasion was significantly associated with lymph node metastases. Only lymph node metastases and tumor differentiation was associated with decreased OS and DFS.

### Table 2  Relationship between PET parameters and histopathologic parameters and lymph node metastases.

| Variables | Lateral lymph node metastasis | p-value |
|-----------|-------------------------------|---------|
|           | Positive | Negative |         |
| TNM       |          |          |         |
| Stage 1–2 | 3        | 10       | 0.005   |
| Stage 3–4 | 16       | 10       |         |
| Differentiation | | | |
| Poor dif. | 10       | 7        | 0.658   |
| Med dif.  | 5        | 7        |         |
| Well dif. | 4        | 6        |         |
| pT stage  |          |          |         |
| T1        | 1        | 2        | 0.0585  |
| T2        | 11       | 14       |         |
| T3–T4     | 7        | 4        |         |
| PN-PV inv |          |          |         |
| PNor PV(+) | 8       | 2        | 0.003   |
| PN or PV(-) | 7      | 22       |         |
| SUV$_{\text{max}}$ |          |          |         |
| ≥ Median level | 11     | 11       | 0.307   |
| ≤ Median level | 8       | 9        |         |
| TLG       |          |          |         |
| ≥ Median level | 13     | 9        | 0.721   |
| ≤ Median level | 6       | 11       |         |
| MTV       |          |          |         |
| ≥ Median level | 12     | 10       | 0.759   |
| ≤ Median level | 7       | 10       |         |

Assessed using the two-sided Fisher’s exact test or the χ² test. PN, Perineural Invasion; PV, Perivascular Invasion.
Our study had several limitations, including its retrospective design, small number of patients and lack of 5 years OS and DFS. Head and neck cancers show a disparity in natural course or clinical behavior depending on primary location and histopathologic properties.

Conclusion

In conclusion, pretreatment MTV, TLG and SUVmax did not predict poor prognosis in our study. Only tumor differentiation and lymph node metastases were associated with lower survival. Perineural and perivascular invasion and TNM stage were the predictors of lymph node metastases. Additional prospective studies with a larger number of patients are needed to validate the prognostic predictors of these functional biomarkers derived from PET/CT.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Allal AS, Dulguerov P, Allaua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–404.
2. Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2013;24:208–14.
3. Minn H, Clavo AC, Grénman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous cell carcinoma of the head and neck. J Nucl Med. 1995;36:252–8.
4. Ranstetter BF 4th, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT, Raman S, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005;235:580–6.
5. Cho JK, Ow TJ, Lee AJ, Smith RV, Schlecht NF, Schiff BA, et al. Preoperative 18F-FDG-PET/CT vs. contrast enhanced CT to identify regional nodal metastasis among patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2017;157(3):439–47.
6. Ak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: A systematic review and meta-analysis. J Nucl Med. 2014;55:845–80.
7. Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol. 2010;49:201–8.
8. Kim BH, Kim SJ, Kim K, Kim H, Kim SJ, Kim WJ, et al. High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma. Ann Nucl Med. 2015;29:729–31.
9. Suzuki H, Tamaki T, Nishio M, Nakata Y, Hanai N, Nishikawa D, et al. Total lesion glycolysis on FDG PET/CT before salvage surgery predicts survival in laryngeal or pharyngeal cancer. Oncotarget. 2018;9:19115–22.
10. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559–66.
11. Machtay M, Natwa M, Andrei J, Hyslop T, Anne PR, Lavarno J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 2009;31:195–201.
12. Ryu I5, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. J Nucl Med. 2013;54:1032–8.
13. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer adding value to clinical staging. J Nucl Med. 2012;53:709–15.
14. YG Abd El-Hafez, Moustafa HM, Khalil HF, Liao CT, Yen TC. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261–8.
15. Le Tourneau C, Jung GM, Borel C, Bronner G, Fliesch H, Velten M. Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. Acta Otolaryngol. 2008;128:706–12.
16. Langendijk JA, de Jong MA, Leemans CR, de Bree R, Smeele LE, Doornaert P, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int J Radiat Oncol Biol Phys. 2003;57:693–700.
17. Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnowski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys. 2003;56:399–412.